Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.52 |
| ▸ | PPARA | Q07869 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713267 | 0.95 | PPARG (0.52) | PPARGPPARANPC1PPARDRAB9A | |
| SCHEMBL6713340 | 0.95 | NPC1 (0.53) | PPARGPPARANPC1PPARDKMT2A | |
| SCHEMBL6716421 | 0.93 | PPARG (0.54) | PPARGPPARANPC1PPARDRAB9A | |
| SCHEMBL6715252 | 0.91 | PPARG (0.47) | PPARGPPARANPC1PPARDRAB9A | |
| SCHEMBL6713238 | 0.91 | RAB9A (0.57) | PPARGPPARANPC1PPARDKMT2A | |
| SCHEMBL6715250 | 0.91 | PPARG (0.47) | PPARGPPARANPC1PPARDRAB9A | |
| SCHEMBL6715242 | 0.91 | PPARG (0.47) | PPARGPPARANPC1PPARDRAB9A | |
| SCHEMBL6716279 | 0.91 | PPARG (0.52) | PPARGPPARANPC1PPARDKMT2A | |
| SCHEMBL6715583 | 0.91 | PPARG (0.56) | PPARGPPARANPC1 | |
| SCHEMBL6714895 | 0.91 | NPC1 (0.49) | PPARGNPC1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | claimed |
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | PPARG 23/4885PPARA 71/4885NPC1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.